Growth factors as treatment for inflammatory bowel disease: a concise review of the evidence toward their potential clinical utility.
In the process of inflammation and repair of the intestinal mucosa in inflammatory bowel disease (IBD), there occurs a complex and an unknown interplay of innate and adaptive immune mechanisms. This interaction of factors may explain why IBD is characterized by a relapsing and remitting clinical course. Different components of innate immunity, hormones and interleukins in IBD have been suggested to be impaired. The growth hormone, epidermal growth factor, keratinocyte growth factor and colony-stimulating factors have emerged as potential tools for the modulation of intestinal inflammation and repair. Despite promising results of initial studies, the evidence that justify treatment of patients in clinical practice is not enough as some of the trials are nonrandomized or included a small number of patients. In this concise review, we provide a summary of the most recent and relevant evidence regarding the potential therapeutic effects of growth factors in IBD.
Barahona-Garrido
Josué
J
Inflammatory Bowel Disease Clinic, Department of Gastroenterology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City; Universidad Nacional Autónoma de México, Mexico City, Mexico. gastromedic@gmail.com
Hernández-Calleros
Jorge
J
García-Juárez
Ignacio
I
Yamamoto-Furusho
Jesús K
JK
D013006:Growth Hormone / Q000627:therapeutic use*; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy*; D011994:Recombinant Proteins; D012074:Remission Induction / Q000379:methods; D016896:Treatment Outcome
D011994:Recombinant Proteins; D013006:Growth Hormone